Launch Of Vyvgart Exceeds Argenx’s Expectations

‘Pipeline in A Product’ Off To Strong Start In US

04 Mar 2022

Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.

false start — Argenx fast out of the blocks with Vyvgart launch • Source: Alamy

The decision to go it alone in marketing the rare disease drug Vyvgart in the US looks a wise one for argenx N.V., with the Belgian-Dutch biotech off to a strong start following the therapy's approval for generalized myasthenia gravis (gMG).

The US Food and Drug Administration gave the green light to Vyvgart (efgartigimod), Argenx’s first approved product, on 17 December for adults who are anti-acetylcholine receptor (AChR) antibody positive, a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

19 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.